Supplement test requirements for "positive identification" of ingredients sought by FDA.
SUPPLEMENT GMP GUIDELINES FOR "POSITIVE IDENTIFICATION" OF INGREDIENTS may be needed, FDA suggests in an advance notice of proposed rulemaking published in the Feb. 6 Federal Register. In requesting comments on aspects of GMPs that may not have been fully covered in the November 1995 industry-proposed version of supplement GMPs, FDA asks interested parties what might be considered "appropriate testing requirements to provide positive identification of dietary ingredients, particularly plant materials, used in dietary supplements."
More from Archive
More from Pink Sheet
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.
Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.